Mark Voll bought $20k of RNXT
Chief Financial Officer at RenovoRx, Inc.. 25,000 shares at an average of $0.79, traded May 19, 2026, filed May 21, 2026.
Score components
- +22RoleCFO
- 0Trade size$20k at market
- +6Relative to holdingsHoldings up 21%
- +18Price context10% above the 52-week low; 43% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-024726, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2026 | POpen-market purchase Common Stock | +25,000 | $0.79 | $20k | 142,380 | May 21, 2026 |
Related signals
Other insiders at RenovoRx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $9,975 10,000 shares | +1% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $8,424 9,795 shares | +1% | |
| 31Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $169 205 shares | +0% | |
| 46Moderate | RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $4,507 5,000 shares | +1% | |
| 41Moderate | RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $4,262 5,000 shares | +2% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $10k 12,000 shares | +2% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $9,600 10,000 shares | +1% | |
| 33Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $18k 22,000 shares | +3% | |
| 33Weak | RNXTbuy RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $9,297 10,000 shares | +3% | |
| 25Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $29k 21,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.